Buy & Sell Royal Caribbean Cruises Ltd (RCL) – Royal Caribbean Cruises Ltd Price Today
Aura AI Summary
Key Stats
- $76.99BMarket Cap
- Consumer CyclicalSector
- -27.01%3M Drawdown
- $98.27BEnterprise Value
- 1.74%Dividend Yield
- 77% Buy | 23% SellTrading Activity
- 75 daysTypical Hold Time
Royal Caribbean Cruises Ltd (RCL) is currently valued at a market capitalization of $76.99B, with an enterprise value of $98.27B. Over the past 52 weeks, Royal Caribbean Cruises Ltd has traded between a low of $228.01 and a high of $365.84, highlighting its annual price range. Over the past three months, Royal Caribbean Cruises Ltd has recorded a drawdown of -27.01%, reflecting recent price volatility. Royal Caribbean Cruises Ltd offers a dividend yield of 1.74%, with the most recent dividend of $1.50 paid on 06 Mar 26. On average, investors hold Royal Caribbean Cruises Ltd for approximately 75 days, indicating typical investor behavior on the platform.
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Most Recent News
CallPhantom scam apps on Google Play fake call logs but charge real money, downloaded 7.3M+ times.
ESET researchers uncovered 28 fraudulent Android apps named CallPhantom on Google Play that falsely claim to provide call logs, SMS, and WhatsApp history for any phone number in exchange for payment. These apps, downloaded over 7.3 million times, gen...
Oculis secures FDA agreement on trial design for Privosegtor in optic neuritis treatment
Oculis Holding AG has received FDA Special Protocol Assessment (SPA) approval for its Phase 3 PIONEER-1 trial of Privosegtor, a novel neuroprotective drug for optic neuritis (ON). This agreement confirms the trial design is suitable to support a futu...
Pakistan’s HBL launches Temenos Core Banking, modernizing 40M accounts across 200 branches.
Habib Bank Limited (HBL) in Pakistan has successfully implemented Temenos Core Banking, marking a major modernization effort. The initial phase migrated accounts from 200 branches, supporting both Conventional and Islamic banking. Once fully deployed...